Ondine Biomedical targets US regulatory milestone after £10m raise and positive Phase 3 results

Ondine targets an FDA pre-NDA meeting in Q1 2027 and NDA submission mid-2027 after positive 5,188-patient Phase 3 results and a £10m raise.

• £10m raised at 10p: Ondine priced the raise at a modest premium to its pre-announcement closing price, timed right after positive LANTERN Phase 3 top-line results.
• LANTERN trial scale: The Phase 3 study enrolled 5,188 patients across 18 hospitals in the US and Canada, testing Steriwave nasal photodisinfection.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.